No Data
Satellos Bioscience Receives Rare Pediatric Disease Designation From FDA for Duchenne Treatment
Satellos Bioscience Inc. Brief: Adds Trial Will Evaluate the Safety and Pharmacokinetic Properties of SAT-3247 in Healthy Human Volunteers
Satellos Bioscience Inc. Brief: Co Says Intends to Submit a Regulatory Package in July to Initiate a First-in-human Phase 1 Clinical Trial, in Q3 2024
Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
Satellos Bioscience Inc. Opens the Market
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
